ArticleiScience2026
A dual space MRI radiomic network signature for risk stratification and subtyping of mild cognitive impairment.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild cognitive impairment (MCI) is a clinically heterogeneous prodromal stage of Alzheimer's disease (AD) in which accurate risk stratification could support earlier intervention and more efficient trial design. Using baseline T1-weighted MRI from the Alzheimer's Disease Neuroimaging Initiative and the National Alzheimer's Coordinating Center cohorts, we developed a dual-space anatomical radiomic-network signature that integrates regional radiomic features and radiomics similarity network metrics extracted in standard and native spaces. The signature improved prediction of MCI-to-AD conversion relative to regional volumetric and clinical models, achieved consistent external validation performance, and separated participants into high- and low-risk groups. The same feature set identified five imaging-defined MCI subtypes with distinct anatomical patterns, conversion risks, and clinical, APOE ε4, and cerebrospinal fluid biomarker profiles; fronto-parietal and parahippocampal-temporal subtypes showed the highest risk. These findings support structural MRI radiomic-network profiling as a complementary framework for individualized prognosis and cohort stratification in AD research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.